Latest Articles

Publication Date
Anti-Müllerian hormone decreased in women with superficial peritoneal endometriosis and associated with an elevated inflammatory profile.

Endometriosis is a common, inflammatory condition impacting 200 million women and those assigned female at birth, where 25-40% experience infertility. Ovarian endometriosis is known to decrease anti-Mullerian hormone (AMH) levels …

Published: May 19, 2026, midnight
Piezo1 mediates hypoxia-induced endometriosis fibrosis via the mtDNA -dependent cGAS-STING pathway.

Endometriosis (EMs) is a prevalent gynecological disorder characterized by the ectopic growth of functional endometrial tissue, and its fibrotic pathology represents a primary contributor to chronic pain and infertility in …

Published: May 19, 2026, midnight
Hypoxia-mediated epigenetic silencing of YTHDF2 promotes endometriosis progression via the NFE2L1-NF-κB axis.

Endometriosis (EMs) is a chronic inflammatory disease characterized by ectopic growth of endometrial-like tissues. N6-methyladenosine (m6A) modification regulates diverse cellular processes, yet its role in EMs remains unclear. Here, we …

Published: May 19, 2026, midnight
Turning Challenges into Success: Successful Pregnancy in Advanced Maternal Age with Adenomyosis Using Prolonged GnRH Agonist Protocol: A Case Report.

Advanced maternal age (AMA) is a major challenge in reproductive medicine, compounded by coexisting conditions such as adenomyosis and endometriosis, which impair oocyte competence and endometrial receptivity. Prolonged gonadotropin-releasing hormone …

Published: May 19, 2026, midnight
Ultrasound-Guided Diagnosis and Treatment of Postsurgical Peripheral Nerve Entrapment in Persistent Pelvic Pain.

Postsurgical peripheral neuropathic pain may be overlooked in patients with chronic pelvic and inguinal pain when overlapping etiologies coexist. This case report describes an ultrasound-guided diagnostic and therapeutic approach for …

Published: May 19, 2026, midnight
Merck's Sac-TMT Shows Promise in Advanced Endometrial Cancer Tri - GuruFocus

Merck's Sac-TMT Shows Promise in Advanced Endometrial Cancer Tri GuruFocus

Published: May 18, 2026, 11:38 p.m.
Merck announces trial results for ADC that addresses unmet needs for patients with advanced endometrial cancer - PharmaLive

Merck announces trial results for ADC that addresses unmet needs for patients with advanced endometrial cancer PharmaLive

Published: May 18, 2026, 1:38 p.m.
Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer - Targeted Oncology

Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer Targeted Oncology

Published: May 18, 2026, 1:33 p.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!